Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative disorder after solid organ transplantation in children

2018 ◽  
Vol 22 (2) ◽  
pp. e13133 ◽  
Author(s):  
Fang Kuan Chiou ◽  
Sue V. Beath ◽  
Gwen M. Wilkie ◽  
Mark A. Vickers ◽  
Bruce Morland ◽  
...  
Keyword(s):  
Organ Transplantation ◽  
T Lymphocyte ◽  
Lymphoproliferative Disorder ◽  
Cytotoxic T Lymphocyte ◽  
Solid Organ Transplantation ◽  
Solid Organ ◽  
Post Transplant

Hematologic Disorders after Solid Organ Transplantation

Hematology ◽  
2010 ◽  
Vol 2010 (1) ◽  
pp. 281-286 ◽  
Author(s):  
Eileen P. Smith
Keyword(s):  
Organ Transplantation ◽  
Graft Versus Host Disease ◽  
Lymphoproliferative Disorder ◽  
Hemophagocytic Syndrome ◽  
Opportunistic Infections ◽  
Solid Organ Transplantation ◽  
Solid Organ ◽  
Hematologic Disorders ◽  
Graft Versus Host ◽  
Post Transplant

Abstract The evaluation of hematologic disorders after solid organ transplantation (SOT) must take into account issues unique to the post-transplant setting that influence the development of anemia and single or multi-lineage cytopenias. Attention to the time of onset of cytopenia(s) is important, because the disorders of passenger lymphocyte syndrome, transplant-related thrombotic microangiopathy, hemophagocytic syndrome, and graft-versus-host disease typically occur during the first few months after SOT, and post-transplant lymphoproliferative disorder usually occurs within the first year. Drug-related anemia and cytopenia(s) occur due to a variety of mechanisms, including drug-induced hemolysis and marrow suppression and perturbation of T-cell subsets by the immunosuppressive agents, leading to immune dysregulation and autoimmunity. Viral infections can cause direct suppression of hematopoiesis, and a variety of opportunistic infections can precipitate acquired hemophagocytic syndrome, a frequently lethal systemic inflammatory disorder. Early investigation of pancytopenia by bone marrow biopsy is warranted, because it is often the presenting symptom of one or multiple life-threatening pathologies after SOT, such as graft-versus host disease, post-transplant lymphoproliferative disorder, hemophagocytic syndrome, or severe opportunistic infections, and these entities may have a better prognosis if early interventions are undertaken.

scholarly journals Pediatric T-cell post-transplant lymphoproliferative disorder after solid organ transplantation

2007 ◽  
Vol 50 (2) ◽  
pp. 415-418 ◽  
Author(s):  
Fan Yang ◽  
Ying Li ◽  
Raul Braylan ◽  
Stephen P. Hunger ◽  
Li-Jun Yang
Keyword(s):  
T Cell ◽  
Organ Transplantation ◽  
Lymphoproliferative Disorder ◽  
Solid Organ Transplantation ◽  
Solid Organ ◽  
Post Transplant

scholarly journals Malignant Post-Transplant Lymphoproliferative Disorder of Nasopharynx in Myelodysplastic Disorder

Healthcare ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 217
Author(s):  
Chih-Wei Luan ◽  
Chih-Cheng Chen ◽  
Kam-Fai Lee ◽  
Ming-Shao Tsai ◽  
Yao-Te Tsai ◽  
...  
Keyword(s):  
Organ Transplantation ◽  
Lymphoproliferative Disorder ◽  
Histopathological Examination ◽  
Solid Organ Transplantation ◽  
Low Grade ◽  
Solid Organ ◽  
Hematopoietic Stem ◽  
Post Transplant ◽  
Low Dose Radiotherapy

(1) Background: Post-transplant lymphoproliferative disorder (PTLD) is a hematological disease and occurs because of immunosuppression after organ transplantation. Only a few studies have reported PTLD in the nasopharynx. In most cases, PTLD developed after solid organ transplantation, and cases of PTLD after bone marrow transplantation, are uncommon. (2) Case presentation: We report the case of a 40-year-old woman with myelodysplastic disorder who underwent hematopoietic stem cell transplantation (HSCT). After 3 months, she developed low-grade fever, progressive nasal obstruction, and bloody rhinorrhea. Endoscopy revealed a mass completely occupying the nasopharynx. A polymorphic PTLD was diagnosed on the basis of histopathological examination results. Reduction in immunosuppression and low-dose radiotherapy were prescribed for treatment. After a 3-year follow-up, no recurrence of PTLD or myelodysplastic disorder was detected. (3) Conclusions: While nasopharyngeal PTLD is rare, a routine examination of the nasopharynx should be considered in the post-transplant follow-up of patients for early detection and treatment of PTLD.

Identification of high-risk monomorphic post-transplant lymphoproliferative disorder following solid organ transplantation

2020 ◽  
pp. 1-9
Author(s):  
Timothy J. Voorhees ◽  
Kavya K. Kannan ◽  
Jonathan Galeotti ◽  
Natalie Grover ◽  
Rakhee Vaidya ◽  
...  
Keyword(s):  
High Risk ◽  
Organ Transplantation ◽  
Lymphoproliferative Disorder ◽  
Solid Organ Transplantation ◽  
Solid Organ ◽  
Post Transplant

Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution

2007 ◽  
Vol 86 (8) ◽  
pp. 599-607 ◽  
Author(s):  
Sylvain Choquet ◽  
Stephan Oertel ◽  
Veronique LeBlond ◽  
Hanno Riess ◽  
Nathalie Varoqueaux ◽  
...  
Keyword(s):  
Organ Transplantation ◽  
Lymphoproliferative Disorder ◽  
Solid Organ Transplantation ◽  
Solid Organ ◽  
Post Transplantation

A systematic review of post-transplant lymphoproliferative disorder after lung transplant.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e19046-e19046
Author(s):  
Mobeen Zaka Haider ◽  
Zarlakhta Zamani ◽  
Fnu Kiran ◽  
Hasan Mehmood Mirza ◽  
Muhammad Taqi ◽  
...  
Keyword(s):  
Lymphoproliferative Disorder ◽  
Lung Transplant ◽  
Late Onset ◽  
Adult Population ◽  
Solid Organ Transplantation ◽  
Chemotherapeutic Agents ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Post Transplant ◽  
Lung Transplant Recipients

e19046 Background: Post-transplant lymphoproliferative disorder (PTLD) is a serious complication after solid organ transplantation. This study aims to explore the association of PTLD diagnosed after lung transplant with infectious agents and immunosuppression regimen, explore types of PTLD, and their outcome. Methods: Following the PRISMA guideline, we searched the literature on PubMed, Cochrane, Embase, and clinicaltrials.gov. 1741 articles were screened and included five studies. Results: We analyzed data from five studies, n=13,643 transplant recipients with n=287 (2.10%) developed PTLD. Four studies showed that 32/63 (51%) PTLD patients were male and 31 (49%) were female. Three studies reported 53/55 (96.4%) patients were EBV positive at PTLD diagnosis. Courtwright. et al, reported that 217/224 (97%) PTLD was associated with either EBV positive donor or recipient. Four studies showed that the monomorphic B cell type 48/63 (76%) was the most common histological type of PTLD diagnosed with DLBCL the most common subtype 31/48 (64.6%). Data from 3 studies showed that the onset of PTLD following lung transplant varies with a median duration of 18.3 months (45 days to 20.2 years). Three studies showed that 26/55 (47.3%) patients had early-onset (≤ 1 yr of Tx) and 29/55 (52.7%) patients had late-onset PTLD (> 1 yr of Tx). Management of PTLD included a reduction in immunosuppression including corticosteroids, CNI, purine synthesis inhibitors, Rituximab, and chemotherapeutic agents. Three studies showed a mortality rate of 30/45 (66.7%) and 13/30 (43.3%) deaths were PTLD related. Conclusions: Our review concludes that PTLD is a serious complication, only 2% of lung transplant recipients developed PTLD. EBV seropositivity is the most factor associated with PTLD diagnosis. Monomorphic PTLD was reported as the most common type in the adult population and no association between gender and PTLD was found. The analysis shows that there is a slightly lower incidence of early (≤ 1 yr of Tx) than late-onset (> 1 yr of Tx) PTLD. Table 1 PTLD after a Lung transplant in adults - a review. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document